Two Cycles of Carboplatin-based Adjuvant Chemotherapy for High-risk Clinical Stage I and Stage IM Non-seminomatous Germ Cell Tumours of the Testis: A HECOG Trial

Anticancer Research

Volumn 23, Issue 5 B, 2003, Pages 4239-4244

  Pectasides, Dimitrios ^a   Skarlos, Dimosthenis ^b   Dimopoulos, Athanasios Meletios ^c   Farmakis, Dimitrios ^a   Pectasides, Melina ^a   Fountzilas, George ^d   Aravantinos, Gerasimos ^e  

^a METAXA CANCER HOSPITAL   (Greece)

^b Henry Dynan Hospital   (Greece)

^c UNIVERSITY OF ATHENS   (Greece)

^d ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^e AGII ANARGIRI CANCER HOSPITAL   (Greece)

Author keywords

Adjuvant chemotherapy; Germ cell tumours; High risk; Non seminomas

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CARBOPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; METHOTREXATE; PACLITAXEL; PLATINUM; TUMOR MARKER;

ADOLESCENT; ADULT; ALOPECIA; ANEMIA; ARTICLE; BLOOD VESSEL; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CAUSE OF DEATH; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG FEVER; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; EMBRYONAL CARCINOMA; FATIGUE; FEBRILE NEUTROPENIA; FOLLOW UP; HIGH RISK PATIENT; HUMAN; INVASIVE CARCINOMA; LIVER METASTASIS; LUNG METASTASIS; LUNG TOXICITY; MALE; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; NON SEMINOMATOUS GERMINOMA; OTOTOXICITY; PARAAORTIC LYMPH NODE; PRIORITY JOURNAL; SALVAGE THERAPY; STOMATITIS; TESTIS; THROMBOCYTOPENIA; YOLK SAC TUMOR;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CARBOPLATIN; CARCINOMA, EMBRYONAL; CHEMOTHERAPY, ADJUVANT; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; GERMINOMA; HUMANS; MALE; NEOPLASM STAGING; ORCHIECTOMY; PROSPECTIVE STUDIES; TESTICULAR NEOPLASMS;

EID: 0344872710     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Freedman LS, Parkinson MC, Jones WG et al: Histopathology in the prediction of relapse of patients with stage I testicular teratoma treated by orchidectomy alone. Lancet 2: 294-298, 1987.
2. Read G, Stenning SP, Cullen MH et al: Medical Research Council prospective study of surveillance for stage I testicular teratoma. Medical Research Council Testicular Tumors Working Party. J Clin Oncol 10: 1762-1768, 1992.
3. Sturgeon JF, Jewett MA, Alison RE et al: Surveillance after orchidectomy for patients with clinical stage I nonseminomatous testis tumors. J Clin Oncol 10: 564-568, 1992.
4. Donohue JP, Thornhill JA, Foster RS, Rowland RG and Bihrle R: Retroperitoneal lymphadenectomy for clinical stage A testis cancer (1965 to 1989): modifications of technique and impact on ejaculation. J Urol 149: 237-243, 1993.
5. Cullen MH, Stenning SP, Parkinson MC et al: Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council report. J Clin Oncol 14: 1106-1113, 1996.
6. Pont J, Albrecht W, Postner G, Sellner F, Angel K and Holtl W: Adjuvant chemotherapy for high-risk clinical stage I nonseminomatous testicular germ cell cancer: long-term results of a prospective trial. J Clin Oncol 14: 441-448, 1996.
7. Bohlen D, Borner M, Sonntag RW, Fey MF and Studer UE: Long-term results following adjuvant chemotherapy in patients with clinical stage I testicular nonseminomatous malignant germ cell tumors with high risk factors. J Urol 161: 1148-1152, 1999.
8. Dearnaley DP, Fossa SD, Kaye SB et al: Adjuvant bleomycin, vincristine and cisplatin (BOP) for high risk clinical stage I (HRCSI) non-seminomatous germ cell tumours (NSGCT). A Medical Research Council (MRC) pilot study. Proc Am Soc Clin Oncol 17: 309a, 1998.
9. McLeod DG, Weiss RB, Stablein DM et al: Staging relationships and outcome in early stage testicular cancer: a report from the Testicular Cancer Intergroup Study. J Urol 145: 1178-1183, 1991.
10. Horwich A and Peckham MJ: Surveillance after orchidectomy for clinical stage I germ-cell tumours of the testis. Prog Clin Biol Res 269: 471-479, 1988.
11. Skinner DG: The management of germ cell tumors of the testis: an overview. Semin Urol 2: 189-193, 1984.
12. Javadpour N, Canning DA, O'Connell KJ and Young JD: Predictors of recurrent clinical stage I nonseminomatous testicular cancer. A prospective clinicopathologic study. Urology 27: 508-511, 1986.
13. Bajorin DF, Sarosdy MF, Pfister DG et al: Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study. J Clin Oncol 11: 598-606, 1993.
14. Horwich A, Sleijfer DT, Fossa SD et al: Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. J Clin Oncol 15: 1844-1852, 1997.
15. Puch RCB and Cameron KM: Teratoma. In: Pathology of the Testis (Puch RCB, ed). London, Blackwell Scientific Publications. 1976, pp 199-224.
16. Peckham MJ: Investigations and staging: general aspects and staging classification. In: The Management of Testicular Tumours (Peckham MJ, ed). London, Edward Arnold. 1971, pp 89-101.
17. Cullen M and James N: Adjuvant therapy for stage I testicular cancer. Cancer Treat Rev 22: 253-264, 1996.
18. Donohue JP and Foster RS: Retroperitoneal lymphadenectomy in staging and treatment. The development of nerve-sparing techniques. Urol Clin North Am 25: 461-468, 1998.
19. Sesterhenn IA, Weiss RB, Mostofi FK et al: Prognosis and other clinical correlates of pathologic review in stage I and II testicular carcinoma: a report from the Testicular Cancer Intergroup Study. J Clin Oncol 10: 69-78, 1992.
20. Williams SD, Stablein DM, Einhorn LH et al: Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer. N Engl J Med 317: 1433-1438, 1987.
21. Sandeman TF and Yang C: Results of adjuvant chemotherapy for low-stage nonseminomatous germ cell tumors of the testis with vascular invasion. Cancer 62: 1471-1475, 1988.
22. Gimmi S, Sonntag R, Brunner K et al: Adjuvant treatment of high risk (HR) clinical stage I testicular carcinoma (TC) with cisplatin (C), bleomycin (B) and vinblastine (V) or etoposide (E). Proc Am Soc Clin Oncol 9: 140, 1990.
23. Madej G and Pawinski A: Risk-related adjuvant chemotherapy for stage I non-seminoma of the testis. In: New Trends of Diagnostics and Treatment of Testicular Tumours, 3rd International Symposium on Advances in Urologic Oncology. Sanremo 1991, p 51.
24. Oliver RT, Raja MA, Ong J and Gallagher CJ: Pilot study to evaluate impact of a policy of adjuvant chemotherapy for high risk stage 1 malignant teratoma on overall relapse rate of stage 1 cancer patients. J Urol 148: 1453-1455, 1992.
25. Studer UE, Fey MF, Calderoni A, Kraft R, Mazzucchelli L and Sonntag RW: Adjuvant chemotherapy after orchiectomy in high-risk patients with clinical stage I non-seminomatous testicular cancer. Eur Urol 23: 444-449, 1993.
26. Chevreau C, Soulie M, Rischmann P et al: Adjuvant chemotherapy in high risk stage I non-seminomatous germ cell tumors. Proc Am Soc Clin Oncol 16: 320a, 1997.
27. Abratt RP, Pontin AR, Barnes RD and Reddi BV: Adjuvant chemotherapy for stage I non-seminomatous testicular cancer. S Afr Med J 84: 605-607, 1994.
28. Ondrus D, Goncalves F, Kausitz J, Mat'oska J and Belan V: The value of prognostic factors in the management of stage I nonseminomatous germ cell testicular tumors (NSGCT). Neoplasma 43: 195-197, 1996.
29. Kollmannsberger C, Beyer J, Droz JP et al: Secondary leukemia following high cumulative doses of etoposide in patients treated for advanced germ cell tumors. J Clin Oncol 16: 3386-3391, 1998.
30. Lampe H, Horwich A, Norman A, Nicholls J and Dearnaley DP: Fertility after chemotherapy for testicular germ cell cancers. J Clin Oncol 15: 239-245, 1997.